RT Journal Article
SR Electronic
T1 M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6939
OP 6943
DO 10.21873/anticanres.13915
VO 39
IS 12
A1 CSABA PUSZTAI
A1 MARIA V. YUSENKO
A1 DANIEL BANYAI
A1 ARPAD SZANTO
A1 GYULA KOVACS
YR 2019
UL http://ar.iiarjournals.org/content/39/12/6939.abstract
AB Background/Aim: In spite of early detection, appoximately 15% of the small renal cell carcinomas (RCC) will develop metastasis within 5 years follow-up. The aim of this study was to identify new biomarkers to estimate the postoperative relapse of the most common conventional RCC. Patients and Methods: Tissue multi arrays of conventional RCC without metastasis at the time of operation from a cohort of 634 patients were analysed by immunohistochemistry for expression of the chitinase 3-like protein 2 (CHI3L2). Cancer specific survival of patients was estimated with Kaplan–Meier analysis, univariate and multivariate Cox regression models. Results: Kaplan–Meier analysis estimated a shorter cancer-free survival for patients with CHI3L2 positive tumors. In multivariate analysis, the CHI3L2 positivity associated with a 3.5 times higher risk for tumor relapse (p<0.001). Conclusion: Expression of CHI3L2 in tumor cells of conventional RCC define a group of patients at high risk for postoperative progression.